Hirokazu Taniguchi

ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 14

Top Venues

Thoracic cancer

Nature communications

Translational lung cancer research

Cancer science

Sloan Kettering Institute

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Sloan Kettering Institute Sep 11 2019

United States

Research Fellow :: Rudin lab

Publications

Hirokazu Taniguchi, Kazuto Ashizawa, Hiroshi Mukae
Can a dysfunctional T-cell gene signature predict nonresponse to PD-1 blockade in non-small cell lung cancer? Translational lung cancer research 13 (8) (2024)
Fumiko Hayashi, Kazumasa Akagi, Hirokazu Taniguchi, Toyoshi Matsutake, Hiromi Kawahara, Ichiro Sekine, Hiroshi Gyotoku, Shinnosuke Takemoto, Hiroshi Soda, Kazuto Ashizawa, Hiroshi Mukae
TIM-3 expression induces resistance to PD-1 inhibitor in G-CSF-producing lung spindle cell carcinoma: A case report. Thoracic cancer (2023)
Hiromi Tomono, Hirokazu Taniguchi, Minoru Fukuda, Takaya Ikeda, Seiji Nagashima, Kazumasa Akagi, Sawana Ono, Yasuhiro Umeyama, Midori Shimada, Hiroshi Gyotoku, Shinnosuke Takemoto, Yasushi Hisamatsu, Ryotaro Morinaga, Ryuta Tagawa, Ryosuke Ogata, Yosuke Dotsu, Hiroaki Senju, Hiroshi Soda, Katsumi Nakatomi, Fumiko Hayashi, Nanae Sugasaki, Akitoshi Kinoshita, Hiroshi Mukae
Phase II study of IRInotecan treatment after COmbined chemo-immunotherapy for extensive-stage small cell lung cancer: Protocol of IRICO study. Thoracic cancer (2023)
Ryuta Tagawa, Hiroshi Soda, Yosuke Dotsu, Hiroaki Senju, Satoshi Irifune, Masataka Yoshida, Shota Nakashima, Asuka Umemura, Keisuke Iwasaki, Hirokazu Taniguchi, Shinnosuke Takemoto, Yuichi Fukuda, Hiroshi Mukae
Hypertrophic osteoarthropathy associated with lung cancer: Possible links among hypoxia-inducible factor-1α, vascular endothelial growth factor, and hypervascularization. Thoracic cancer (2023)
Hirokazu Taniguchi, Kazumasa Akagi, Yosuke Dotsu, Tadaaki Yamada, Sawana Ono, Erika Imamura, Hiroshi Gyotoku, Shinnosuke Takemoto, Hiroyuki Yamaguchi, Triparna Sen, Seiji Yano, Hiroshi Mukae
Pan-HER inhibitors overcome lorlatinib resistance caused by NRG1/HER3 activation in ALK-rearranged lung cancer. Cancer science (2022)
Kazumasa Akagi, Hirokazu Taniguchi, Minoru Fukuda, Takuya Yamazaki, Sawana Ono, Hiromi Tomono, Takayuki Suyama, Midori Shimada, Hiroshi Gyotoku, Shinnosuke Takemoto, Hiroyuki Yamaguchi, Yosuke Dotsu, Hiroaki Senju, Hiroshi Soda, Takashi Mizowaki, Yoshio Monzen, Takaya Ikeda, Seiji Nagashima, Yutaro Tasaki, Daisuke Nakamura, Kazutoshi Komiya, Katsumi Nakatomi, Eisuke Sasaki, Koichi Hirakawa, Hiroshi Mukae
Phase I study of amrubicin plus cisplatin and concurrent accelerated hyperfractionated thoracic radiotherapy for limited-disease small cell lung cancer: protocol of ACIST study. Thoracic cancer 13 (16) (2022)
Keiko Tanimura, Tadaaki Yamada, Koutaroh Okada, Kunihiro Nakai, Mano Horinaka, Yuki Katayama, Kenji Morimoto, Yuri Ogura, Takayuki Takeda, Shinsuke Shiotsu, Kosuke Ichikawa, Satoshi Watanabe, Yoshie Morimoto, Masahiro Iwasaku, Yoshiko Kaneko, Junji Uchino, Hirokazu Taniguchi, Kazue Yoneda, Satoaki Matoba, Toshiyuki Sakai, Hisanori Uehara, Seiji Yano, Tetsuro Kusaba, Ryohei Katayama, Koichi Takayama
HER3 activation contributes toward the emergence of ALK inhibitor-tolerant cells in ALK-rearranged lung cancer with mesenchymal features. NPJ precision oncology 6 (1) (2022)
Ryosuke Ogata, Hiroshi Soda, Hiroaki Senju, Masaki Fujioka, Midori Shimada, Koki Yamashita, Satoshi Irifune, Ryuta Tagawa, Yosuke Dotsu, Keisuke Iwasaki, Hirokazu Taniguchi, Shinnosuke Takemoto, Yuichi Fukuda, Hiroshi Mukae
Immunosuppressive tumor microenvironment in extraskeletal myxoid chondrosarcoma: A case of pleural metastases. Thoracic cancer 13 (19) (2022)
Hirokazu Taniguchi, Shinnosuke Takemoto, Mutsumi Ozasa, Noritaka Honda, Takayuki Suyama, Yasuhiro Umeyama, Yosuke Dotsu, Takumi Nakao, Kojima Tomohito, Hiroshi Gyotoku, Hiroyuki Yamaguchi, Taiga Miyazaki, Noriho Sakamoto, Yasushi Obase, Minoru Fukuda, Junya Fukuoka, Hiroshi Mukae
Remarkable response to pembrolizumab with platinum-doublet in PD-L1-low pulmonary sarcomatoid carcinoma: A case report. Thoracic cancer 12 (7) (2021)
Shinnosuke Takemoto, Kazumasa Akagi, Sawana Ono, Hiromi Tomono, Noritaka Honda, Takayuki Suyama, Yasuhiro Umeyama, Yosuke Dotsu, Hirokazu Taniguchi, Daiki Ogawara, Hiroaki Senju, Hiroshi Gyotoku, Nanae Sugasaki, Hiroyuki Yamaguchi, Katsumi Nakatomi, Minoru Fukuda, Hiroshi Mukae
Efficacy of S-1 after pemetrexed in patients with non-small cell lung cancer: A retrospective multi-institutional analysis. Thoracic cancer 12 (17) (2021)
Rong Wang, Tadaaki Yamada, Kenji Kita, Hirokazu Taniguchi, Sachiko Arai, Koji Fukuda, Minoru Terashima, Akihiko Ishimura, Akihiro Nishiyama, Azusa Tanimoto, Shinji Takeuchi, Koshiro Ohtsubo, Kaname Yamashita, Tomoyoshi Yamano, Akihiro Yoshimura, Koichi Takayama, Kyoichi Kaira, Yoshihiko Taniguchi, Shinji Atagi, Hisanori Uehara, Rikinari Hanayama, Isao Matsumoto, Xujun Han, Kunio Matsumoto, Wei Wang, Takeshi Suzuki, Seiji Yano
Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer. Nature communications 11 (1) (2020)
Hirokazu Taniguchi, Tadaaki Yamada, Rong Wang, Keiko Tanimura, Yuta Adachi, Akihiro Nishiyama, Azusa Tanimoto, Shinji Takeuchi, Luiz H Araujo, Mariana Boroni, Akihiro Yoshimura, Shinsuke Shiotsu, Isao Matsumoto, Satoshi Watanabe, Toshiaki Kikuchi, Satoru Miura, Hiroshi Tanaka, Takeshi Kitazaki, Hiroyuki Yamaguchi, Hiroshi Mukae, Junji Uchino, Hisanori Uehara, Koichi Takayama, Seiji Yano
AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells. Nature communications 10 (1) (2019)
Hirokazu Taniguchi, Hiroyuki Yamaguchi, Yosuke Dotsu, Midori Shimada, Hiroshi Gyotoku, Hiroaki Senju, Shinnosuke Takemoto, Takeshi Kitazaki, Masaaki Fukuda, Daiki Ogawara, Hiroshi Soda, Katsumi Nakatomi, Nanae Sugasaki, Akitoshi Kinoshita, Seiji Nagashima, Takaya Ikeda, Yoichi Nakamura, Noriho Sakamoto, Yasushi Obase, Minoru Fukuda, Hiroshi Mukae
Phase II study of nedaplatin and amrubicin as first-line treatment for advanced squamous cell lung cancer. Thoracic cancer 10 (9) (2019)
Shinnosuke Takemoto, Minoru Fukuda, Hiroyuki Yamaguchi, Takaya Ikeda, Kazumasa Akagi, Hiromi Tomono, Yasuhiro Umeyama, Yosuke Dotsu, Hirokazu Taniguchi, Hiroshi Gyotoku, Hiroaki Senju, Takeshi Kitazaki, Katsumi Nakatomi, Seiji Nagashima, Masaaki Fukuda, Akitoshi Kinoshita, Hiroshi Soda, Hiroshi Mukae
Phase II study of ramucirumab and docetaxel for previously treated non-small cell lung cancer patients with malignant pleural effusion: Protocol of PLEURAM study. Thoracic cancer 11 (2) (2019)

Hirokazu Taniguchi.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Hirokazu Taniguchi